{"id":892259,"date":"2025-10-03T09:17:28","date_gmt":"2025-10-03T13:17:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/"},"modified":"2025-10-03T09:17:28","modified_gmt":"2025-10-03T13:17:28","slug":"bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/","title":{"rendered":"BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Oct.  03, 2025  (GLOBE NEWSWIRE) &#8212; <strong>BioAtla, Inc. (Nasdaq: BCAB)<\/strong>, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced that clinical data for its investigational AXL-targeting antibody-drug conjugate (ADC), mecbotamab vedotin (BA3011), will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting to be held at National Harbor, MD from November 5-9, 2025.<\/p>\n<p align=\"justify\">The presentation, titled\u00a0<strong>\u201cMedian OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC\u201d<\/strong>, will be delivered by\u00a0<strong>Dr. Mihaela Druta<\/strong>\u00a0of\u00a0<strong>Moffitt Cancer Center<\/strong>\u00a0on\u00a0<strong>Friday, November 7, 2025<\/strong>. The abstract (#523) will be featured in the poster session, with presentation time to be announced.<\/p>\n<p align=\"justify\">A copy of the presentation materials can be accessed on the \u201cPublication\u201d section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ICtiVe49JgVy9dovpM4RoKVgkYIB4kt0R2Qxcr8PvW3dz00yBSd8TgJpi3Jh6i9bnwvTtMD9S54q56dLIzCDUiW9QYzvoBW_VttWvqgrNFZLw285eA5n-LQh62TWife_2_qnfWSmKGicN6SgCfoFpilud8jkraFh8wA5WjUhZHuAZEVJR6S89wRwURh7cJx9FdixMNlaDgzfwjVLii6uDSmR1O5GTe2BYz-xh1je7AlK5qx5SIxjYBpvyYosDc0CirmuPMXOS98EORcS2H2S6DS9vUIZAfp0a-gNiPSF5x7KDBxgTJxF8K-ZOlvmMUBom1gq0y25gf2G-4hWiLTkPzuZYC8gLUlo9xuX-Mv_vbCJBcX_DKpyGNG907mj0XAxDKSygNaYLKLETKipsmFRHP0jvQuXzbxgMrfOhCmlhfNvTqjkWxWafsmXx5mOe8Ws\" rel=\"nofollow\" target=\"_blank\">www.bioatla.com<\/a> once the presentation has concluded.<\/p>\n<p align=\"justify\">\n        <strong>About BioAtla<sup>\u00ae<\/sup>, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. To learn more about BioAtla, Inc., visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ICtiVe49JgVy9dovpM4RoFYwgv_0GySdgPuaECzeN4MULbdPAGiZiVqi4p2EqWc3ul2W0h6GB1O_8AVUitkNfg==\" rel=\"nofollow\" target=\"_blank\">www.bioatla.com<\/a>.<\/p>\n<p>\n        <strong>Internal Contact:<\/strong><br \/>\n        <br \/>Richard Waldron<br \/>Chief Financial Officer<br \/>BioAtla, Inc.<br \/>rwaldron@bioatla.com<br \/>858.356.8945<\/p>\n<p>\n        <strong>External Contact:<\/strong><br \/>\n        <br \/>Joyce Allaire<br \/>LifeSci Advisors, LLC<br \/>jallaire@lifesciadvisors.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTQwMyM3MTc3NTExIzIxOTAxMzU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWNkZmU5NDEtNTJiNS00YjYyLThjYmUtYWU1ZDEzOWRhNGE3LTEyMDE2ODgtMjAyNS0xMC0wMy1lbg==\/tiny\/BioAtla-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced that clinical data for its investigational AXL-targeting antibody-drug conjugate (ADC), mecbotamab vedotin (BA3011), will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting to be held at National Harbor, MD from November 5-9, 2025. The presentation, titled\u00a0\u201cMedian OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC\u201d, will be delivered by\u00a0Dr. Mihaela Druta\u00a0of\u00a0Moffitt Cancer Center\u00a0on\u00a0Friday, November 7, 2025. The abstract (#523) will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-892259","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced that clinical data for its investigational AXL-targeting antibody-drug conjugate (ADC), mecbotamab vedotin (BA3011), will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting to be held at National Harbor, MD from November 5-9, 2025. The presentation, titled\u00a0\u201cMedian OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC\u201d, will be delivered by\u00a0Dr. Mihaela Druta\u00a0of\u00a0Moffitt Cancer Center\u00a0on\u00a0Friday, November 7, 2025. The abstract (#523) will &hellip; Continue reading &quot;BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-03T13:17:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTQwMyM3MTc3NTExIzIxOTAxMzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025\",\"datePublished\":\"2025-10-03T13:17:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/\"},\"wordCount\":334,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTQwMyM3MTc3NTExIzIxOTAxMzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/\",\"name\":\"BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTQwMyM3MTc3NTExIzIxOTAxMzU=\",\"datePublished\":\"2025-10-03T13:17:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTQwMyM3MTc3NTExIzIxOTAxMzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTQwMyM3MTc3NTExIzIxOTAxMzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/","og_locale":"en_US","og_type":"article","og_title":"BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - Market Newsdesk","og_description":"SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced that clinical data for its investigational AXL-targeting antibody-drug conjugate (ADC), mecbotamab vedotin (BA3011), will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting to be held at National Harbor, MD from November 5-9, 2025. The presentation, titled\u00a0\u201cMedian OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC\u201d, will be delivered by\u00a0Dr. Mihaela Druta\u00a0of\u00a0Moffitt Cancer Center\u00a0on\u00a0Friday, November 7, 2025. The abstract (#523) will &hellip; Continue reading \"BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-03T13:17:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTQwMyM3MTc3NTExIzIxOTAxMzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025","datePublished":"2025-10-03T13:17:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/"},"wordCount":334,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTQwMyM3MTc3NTExIzIxOTAxMzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/","name":"BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTQwMyM3MTc3NTExIzIxOTAxMzU=","datePublished":"2025-10-03T13:17:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTQwMyM3MTc3NTExIzIxOTAxMzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTQwMyM3MTc3NTExIzIxOTAxMzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-present-clinical-data-for-mecbotamab-vedotin-ba3011-in-soft-tissue-sarcoma-at-sitc-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=892259"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892259\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=892259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=892259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=892259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}